NCT03845036

Brief Summary

This study is a 3-month, prospective, randomized controlled clinical trial designed to address the efficacy of the DASH dietary program combined with a home-based exercise program, quantified by a step activity monitor, to improve exercise and vascular outcome measures in patients with PAD.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
37mo left

Started Sep 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress35%
Sep 2024May 2029

First Submitted

Initial submission to the registry

February 15, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 19, 2019

Completed
5.6 years until next milestone

Study Start

First participant enrolled

September 16, 2024

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2029

Last Updated

April 17, 2026

Status Verified

April 1, 2026

Enrollment Period

4.7 years

First QC Date

February 15, 2019

Last Update Submit

April 13, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Peak Walking Time

    The change in the time walked on a treadmill test

    3 months

  • Physical Function subscale of quality of life from the Medical Outcomes Study Short-Form 36 questionnaire

    The change in the Physical Function subscale from the pre-test value to the post-test value

    3 months

Secondary Outcomes (3)

  • calf muscle oxygen saturation

    3 months

  • 6-minute walk distance

    3 months

  • high-sensitivity C-reactive protein

    3 months

Study Arms (2)

DASH Diet plus Home-Based Exercise

EXPERIMENTAL

The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.

Behavioral: DASH Diet plus Home-Based Exercise

Home-Based Exercise

ACTIVE COMPARATOR

The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.

Behavioral: Home-Based Exercise

Interventions

The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.

DASH Diet plus Home-Based Exercise

The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.

Home-Based Exercise

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • History of claudication,
  • Presence of PAD, defined by meeting at least one of the following criteria (ABI at rest \< 0.90, or \> 20% decrease in ABI following a heel-rise exercise test in patients with a normal ABI at rest (\> 0.90), or history of peripheral revascularization.

You may not qualify if:

  • absence of PAD, defined by meeting all of the following 3 criteria (ABI at rest \> 0.90), \< 20% decrease in ABI following a heel-rise exercise test, and no history of peripheral revascularization,
  • non-compressible vessels (ABI \> 1.40),
  • rest pain due to PAD (Fontaine stage III; Rutherford Grade II),
  • tissue loss due to PAD (Fontaine stage IV; Rutherford Grade III),
  • use of medications indicated for the treatment of intermittent claudication (cilostazol and pentoxifylline) initiated within three months prior to investigation,
  • peripheral revascularization within one month prior to investigation,
  • active cancer,
  • end stage renal disease defined as stage 5 chronic kidney disease,
  • medical conditions that are contraindicative for exercise according to the American College of Sports Medicine,
  • cognitive dysfunction (mini-mental state examination score \< 24), and
  • failure to complete the baseline tests within three weeks.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

O'Donoghue Research Building, University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73117, United States

RECRUITING

Related Publications (3)

  • Gardner AW, Parker DE, Montgomery PS, Scott KJ, Blevins SM. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial. Circulation. 2011 Feb 8;123(5):491-8. doi: 10.1161/CIRCULATIONAHA.110.963066. Epub 2011 Jan 24.

  • Gardner AW, Parker DE, Montgomery PS, Blevins SM. Step-monitored home exercise improves ambulation, vascular function, and inflammation in symptomatic patients with peripheral artery disease: a randomized controlled trial. J Am Heart Assoc. 2014 Sep 18;3(5):e001107. doi: 10.1161/JAHA.114.001107.

  • Gardner AW, Bright BC, Ort KA, Montgomery PS. Dietary intake of participants with peripheral artery disease and claudication. Angiology. 2011 Apr;62(3):270-5. doi: 10.1177/0003319710384395.

MeSH Terms

Conditions

Intermittent ClaudicationPeripheral Arterial Disease

Interventions

Dietary Approaches To Stop Hypertension

Condition Hierarchy (Ancestors)

Peripheral Vascular DiseasesVascular DiseasesCardiovascular DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsAtherosclerosisArteriosclerosisArterial Occlusive Diseases

Intervention Hierarchy (Ancestors)

Diet TherapyNutrition TherapyTherapeuticsDietNutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Study Officials

  • Andrew Gardner, Ph.D.

    Professor, Department of Medicine, Cardiology

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Andrew Gardner, Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Prospective, randomized controlled clinical trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 15, 2019

First Posted

February 19, 2019

Study Start

September 16, 2024

Primary Completion (Estimated)

May 31, 2029

Study Completion (Estimated)

May 31, 2029

Last Updated

April 17, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations